Who Is Eligible for CAR-T Therapy for Lymphoma? 2026 Patient Guide

Updated: September 2026

CAR-T cell therapy may be an option for patients with certain B-cell lymphomas that have returned after treatment or have not responded adequately.

Eligibility depends on the exact lymphoma subtype, previous treatments, the timing of relapse, current disease status and the patient’s general health. The reviewing team must also determine whether the disease can be controlled while the CAR-T cells are being prepared.

For international patients, an early review may help clarify whether CAR-T is a realistic option before another treatment is started.

Which lymphoma types may be treated with CAR-T?

CAR-T is primarily used for selected B-cell non-Hodgkin lymphomas.

These may include:

• Diffuse large B-cell lymphoma (DLBCL)
• High-grade B-cell lymphoma
• Primary mediastinal large B-cell lymphoma
• DLBCL transformed from follicular lymphoma
• Follicular lymphoma
• Mantle cell lymphoma
• Marginal zone lymphoma
• Certain other relapsed or refractory B-cell lymphomas, depending on the protocol

Eligibility varies considerably between lymphoma subtypes and treatment programs. A treatment approved for one type of lymphoma may not be appropriate or available for another.

CAR-T is not a standard treatment for Hodgkin lymphoma or most T-cell lymphomas. Patients with these diagnoses generally require different treatment approaches or a relevant clinical trial.

What does relapsed or refractory lymphoma mean?

Relapsed lymphoma means that the disease initially responded to treatment but later returned.

Refractory lymphoma means that the lymphoma did not respond adequately, progressed during treatment or returned very soon after treatment.

Both situations may lead to a CAR-T evaluation. However, the timing of relapse is particularly important in aggressive lymphomas such as DLBCL.

A patient whose lymphoma returns within 12 months of first-line treatment may follow a different treatment pathway from a patient whose disease returns several years later.

CAR-T eligibility for DLBCL

Diffuse large B-cell lymphoma is one of the most common indications for CAR-T therapy.

A patient with DLBCL may be considered when:

• The lymphoma did not respond to first-line treatment.
• The disease progressed during treatment.
• The lymphoma returned within 12 months of completing first-line therapy.
• The disease returned after two or more previous treatment lines.
• An autologous stem cell transplant failed.
• The patient is not suitable for a stem cell transplant.
• The lymphoma transformed from an indolent B-cell lymphoma into DLBCL.

For primary refractory disease or relapse within 12 months, CAR-T may be considered as a second-line treatment in selected patients.

When DLBCL returns after a longer remission, salvage chemotherapy followed by autologous stem cell transplantation may remain an important option if the lymphoma is sensitive to chemotherapy and the patient is medically fit.

The treatment decision should therefore consider both the timing of relapse and whether the lymphoma still responds to chemotherapy. Read more about treatment options after R-CHOP fails.

CAR-T eligibility for follicular lymphoma

CAR-T may be considered for selected patients with follicular lymphoma that has returned after several treatments.

The reviewing team may consider:

• The number of previous treatment lines
• How quickly the lymphoma returned
• Whether the disease is becoming more aggressive
• Response to previous antibody and chemotherapy combinations
• Previous treatment with bispecific antibodies
• Whether the lymphoma has transformed into DLBCL
• Current symptoms and disease burden
• The patient’s general health

In commercial treatment pathways, CAR-T is generally considered after at least two previous treatment lines. However, regulatory indications and treatment availability differ between countries and programs.

Patients with transformed follicular lymphoma should be assessed according to the aggressive component of the disease.

CAR-T eligibility for mantle cell lymphoma

CAR-T may be an option for patients with relapsed or refractory mantle cell lymphoma.

Important factors include:

• Previous treatment lines
• Previous exposure to a BTK inhibitor
• Response and resistance to treatments such as ibrutinib, acalabrutinib or zanubrutinib
• Speed of disease progression
• Bone marrow involvement
• Blood counts
• General health and organ function
• Whether the patient can safely wait for CAR-T manufacturing

The exact previous-treatment requirements depend on the CAR-T product and treatment protocol. Some patients may also have other targeted treatments or bispecific antibodies available, so the full treatment sequence should be reviewed.

Can other non-Hodgkin lymphomas be treated with CAR-T?

Some additional B-cell lymphomas may be eligible for CAR-T under specific commercial indications, hospital protocols or clinical trials.

These can include certain cases of:

• Marginal zone lymphoma
• Small lymphocytic lymphoma
• High-grade B-cell lymphoma
• Primary mediastinal B-cell lymphoma
• Transformed indolent lymphoma

The pathology must be reviewed carefully. Terms such as “non-Hodgkin lymphoma” or “B-cell lymphoma” are too broad to determine eligibility.

The application should include the complete pathology report, immunohistochemistry results and, when available, molecular or genetic findings.

CAR-T or stem cell transplant after lymphoma relapse?

CAR-T and autologous stem cell transplantation are different treatment approaches.

A stem cell transplant may remain appropriate when:

• The lymphoma returned after a longer remission.
• The disease responds well to salvage chemotherapy.
• The patient is medically fit for high-dose chemotherapy.
• The treating team believes transplantation offers an appropriate chance of long-term control.

CAR-T may be considered when:

• The lymphoma did not respond to first-line treatment.
• The disease returned within 12 months.
• Salvage chemotherapy did not produce an adequate response.
• The lymphoma returned after a stem cell transplant.
• The patient is not suitable for transplantation.
• Previous treatment history meets the relevant CAR-T protocol.

A patient does not necessarily need to be eligible for a stem cell transplant to qualify for CAR-T.

What health factors affect CAR-T eligibility?

The reviewing team will normally assess:

• General physical condition
• Ability to perform daily activities
• Heart and lung function
• Kidney and liver function
• Blood counts
• Neurological history
• Active or recent infections
• Previous treatment complications
• Other serious medical conditions
• Ability to receive lymphodepleting chemotherapy

A chronic medical condition does not always lead to exclusion. The team considers whether it is stable and whether it increases the risks of CAR-T treatment.

Does age affect CAR-T eligibility for lymphoma?

There is no single universal upper age limit.

Older patients may still qualify when they have adequate organ function and a suitable general condition. Frailty, mobility, cognitive function, other medical problems and caregiver support are often more important than chronological age alone.

However, CAR-T can cause serious complications, including cytokine release syndrome, neurological toxicity, infections and prolonged low blood counts. Older or medically complex patients may therefore require a more detailed assessment.

Read more about the age limit for CAR-T therapy.

Can a patient receive CAR-T with an active infection?

An uncontrolled bacterial, viral or fungal infection will usually delay CAR-T.

The preparatory chemotherapy and CAR-T treatment suppress the immune system and can make an existing infection more dangerous.

A previous infection does not automatically exclude the patient. The team must determine whether it has resolved, remains controlled or requires further treatment before CAR-T.

Does previous treatment with a bispecific antibody affect eligibility?

Previous treatment with a bispecific antibody does not automatically prevent CAR-T.

Bispecific antibodies such as epcoritamab, glofitamab and mosunetuzumab may be used in relapsed B-cell lymphomas. The team will consider:

• Which bispecific antibody was given
• The target of the treatment
• Whether the lymphoma responded
• How long the response lasted
• Why the treatment was stopped
• Current infection status and blood counts
• Whether sufficient T cells can be collected
• Whether the lymphoma still expresses the intended CAR-T target

When both CAR-T and a bispecific antibody are possible, sequencing should be discussed before treatment begins whenever medically practical.

When should an international patient request a review?

An international review may be appropriate when:

• DLBCL did not respond to first-line treatment.
• DLBCL returned within 12 months.
• Lymphoma returned after a stem cell transplant.
• Follicular or mantle cell lymphoma progressed after several treatments.
• CAR-T is unavailable or substantially delayed locally.
• The patient has been placed on a long waiting list.
• A bispecific antibody is being considered.
• The patient was told that age alone prevents CAR-T.
• The patient wants to know whether treatment abroad is medically realistic.

Patients should not stop or delay necessary treatment while waiting for an international review.

The complete process, from initial medical evaluation through treatment and follow-up, requires advance planning. Read more about how long the CAR-T process takes and one patient’s experience of traveling to Israel for CAR-T therapy.

Read patient testimonials >>

Request an individual CAR-T eligibility review

Israeli Hospitals coordinates medical-record reviews for international patients with relapsed or refractory lymphoma.

The reviewing team can assess whether the lymphoma subtype and treatment history may be suitable for CAR-T, whether additional information is required and which next steps can be considered.

Every application is reviewed individually. Submission of medical records does not guarantee eligibility, acceptance, treatment availability or a particular outcome.

Submit the patient’s medical records for an individual CAR-T eligibility review.

Patients and families can also review the latest evidence on CAR-T success rates in lymphoma.

Sources

1. Chong EA, Tomasulo EB, Barta SK. 2026 Update on the Management of Diffuse Large B-Cell Lymphoma . American Journal of Hematology. 2026.
2. CAR T-cell therapy for follicular lymphoma and mantle cell lymphoma . 2022.
3. National Cancer Institute. CAR T Cells: Engineering Immune Cells to Treat Cancer . Updated 2025.